Login
$MGNX
$2.14 -$0.03 (1.38%) After hours

$MGNX SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 8-K: Regulation FD Disclosure

2 November 12, 2026 Legal Notices The information in this slide deck is current as of November 12, 2026, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed wi...

12 Nov 2026 8-K: Results of Operations and Financial Condition
12 Nov 2026 10-Q
03 Nov 2026 Form 4: Vasconcelles Michael, Director

Granted 44,000 Stock Option (right to buy) · Granted 7,500 Restricted Stock Unit

03 Nov 2026 Form 3: Vasconcelles Michael, Director

No securities owned

03 Nov 2026 Form 4: Kuriakose Emil, Director

Granted 44,000 Stock Option (right to buy) · Granted 7,500 Restricted Stock Unit

03 Nov 2026 Form 3: Kuriakose Emil, Director

No securities owned

03 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

ROCKVILLE, MD, November 3, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced th...

23 Oct 2026 8-K: Other Events

2 October 23, 2026 Legal Notices The information in this slide deck is current as of October 23, 2026, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with...

22 Oct 2026 144
07 Oct 2026 Form 4: Bonvini Ezio, Sr VP, Research & CSO

Received 8,000 shares by exercise or conversion ($20.8K)

21 Sep 2026 144
03 Sep 2026 S-8
03 Sep 2026 8-K/A: Financial Statements and Exhibits

Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and liabilities related to its GMP manufacturing operations (the "Purchased Assets"), including it...

20 Aug 2026 Form 4: Peters Jeffrey Stuart, Senior VP, GC, and Secretary

Sold 31,105 shares ($129K)

19 Aug 2026 144
18 Aug 2026 Form 4: Bonvini Ezio, Sr VP, Research & CSO

Received 40,000 shares by exercise or conversion ($104K)

17 Aug 2026 144
14 Aug 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support